Management

Dr. Mahendra N. Deshpande is a President and Chief Executive Officer. His forte is creativity in problem solving, development of novel synthetic routes / processes for bulk drug synthesis, successful implementation of technology in kilo-labs and manufacturing plants. He has managed multiple projects and led a team of scientists (Ph.Ds. and Chem. Engineers). In his 12 years of tenure at Abbott Labs, he developed a number of processes for bulk drug manufacturing from bench to plant. He has published extensively in peer-reviewed journal and made number of scientific presentation worldwide. Dr. Deshpande earned his B.Sc. (Hons.) and M.Sc. degrees from India. He earned another MS degree (Organic Chemistry) at Wichita State University, and a Ph.D. degree in Organic Chemistry at University of Wisconsin, Milwaukee. He completed postdoctoral assignments at Research Triangle Institute in Research Triangle Park, NC and University of North Texas. He was a group leader / Sr. Research Investigator in Process R & D at Abbott Laboratories, N. Chicago, IL, where he oversaw projects in chemical route selection, process development and scaleup in kilolab and pilot plants in USA and Europe. He was the recipient of the Bob Stein award and Chairman's awards for outstanding scientific contributions to several neuroscience projects.

Dr. Rajendra C. Shah is a President and Chief Operating Officer. He received his Ph. D. from Sardar Patel University, India. He has over 20 years of research and development experience in different areas of pharmaceutical research, such as Process R & D, analytical and formulation. During his 10 years of service at Abbott Laboratory, IL, he developed chemical processes in the lab and  transferred the technolologies to pilot plant and manufacturing in USA and Europe. He demonstrated creativity and leadership in problem solving in  process development, polymorphism, crystallization, purification and isolation. Furthermore. he successfully completed process justification for a bulk pharmaceuticals' manufacturing process in order to bring them into compliance with the latest FDA/EPA guide lines. He has handled controlled drug projects and made cGMP deliveries in USA and Europe.  Prior to his tenure in Abbott Labs, Dr.Shah was Sr. Scientist at Lyphomed, IL, where he was responsible for cGMP formulation and Quality Control in a GLP Laboratory (regulated by FDA/EPA and OSHA regulations and guidelines). He managed over 100 formulation products and their analysis. Dr.Shah held a position of Process R &D Manager at Themis Pharmaceutical Ltd., India, where he led a team of chemists and engineers. He developed a highly cost efficient  process for resolution of D2-aminobutanol.

Dr. Richard J. Pariza is a member of the Scientific Advisory board of OrgSyn Laboratory, Inc.  He is also Vice President, Science and Technology, for Cedarburg Pharmaceuticals, Inc., in Grafton, WI, and an officer and Board Member for OncQuest, Inc.  He has had over 20 years of leadership on major projects in the pharmaceutical industry, as Department Manager of Process Research at Abbott Laboratories, Vice President of Chemistry for Protarga, Inc., and a consultant to several major pharmaceutical companies. He was the chairman of a prestigious IUPAC Symposium and has served on/chaired national ACS committees. He was frequently invited to chair sessions and lead discussions at international scientific conferences.  He was a founding Associate Editor for Organic Process Research & Development , the research publication of the American Chemical Society for process research, and now serves on the Editorial Board.  He has more than 20 peer-reviewed publications and 10 patents, and continues to be active in chemical research.

Dr. Mukund Chorghade is a member of the Scientific Advisory board of OrgSyn Laboratory, Inc.  President and Chief Scientific Officer of the Pharmaceutical Sciences Division of D & O Pharmachem, Inc. He has been President of Chorghade Enterprises / CP Consulting, Inc. providing consultations to major American, European and Asian pharmaceutical and biopharmaceutical companies on collaborations with worldwide academic, government and industrial laboratories.                                                              

Dr. Chorghade earned a Ph.D. in Organic Chemistry at Georgetown University in Washington, D. C., in 1982.  He completed postdoctoral appointments at the University of British Columbia, and College de France / Université Louis Pasteur.  He was Vice-President, Chemical Development Sciences at Geltex / Genzyme where he oversaw projects in chemical route selection, process development, chemical manufacturing and formulation of bulk actives to finished dosage forms.  He directed research groups at Dow Chemicals, Abbott Laboratories and CytoMed.  He was the recipient of three “Scientist of the Year Awards” and had the honor of being a featured speaker in several national and international symposia. 

Dr. Chorghade is currently on the Board of Directors of the Northeast Section of American Chemical Society. He serves on the Advisory Board for Organic Process Research and Development, Chimica Oggi and the Nucleus .  Dr. Chorghade has been honored by election to the Royal Society of Chemistry (Elected Fellow); New York Academy of Sciences; American Institute of Chemists (Elected Fellow); World Innovation Foundation (Elected Fellow); AAAS; Sigma Xi; and Indian Society of Bio-Organic Chemists.